Methods of treating cancer
AssigneesFive Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property (No.2) Limited
InventorsDavid Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
Life of this patent
Estimating the term…
Abstract
Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
Claims56
A method of treating cancer having a higher level of FGF2 compared to the level of VEGF in a subject, wherein a higher level of FGF2 compared to the level of VEGF is indicative of therapeutic responsiveness by the cancer to a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule, comprising administering a therapeutically effective amount of an FGFR1 ECD or an FGFR1 ECD fusion molecule to the subject.
A method of treating cancer in a subject, comprising:
- administering a therapeutically effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule to the subject,
- wherein, prior to administration of the FGFR1 ECD or FGFR1 ECD fusion molecule, at least a portion of the cells of the cancer have been determined to have a higher level of FGF2 compared to the level of VEGF, and
- wherein a higher level of FGF2 compared to the level of VEGF in a cancer is indicative of therapeutic responsiveness by the cancer to an FGFR1 ECD or FGFR1 ECD fusion molecule.
A method of identifying a subject who may benefit from treatment with a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule, the method comprising determining the levels of FGF2 and VEGF in a sample obtained from the subject, wherein a higher level of FGF2 compared to the level of VEGF in the sample indicates that the subject may benefit from treatment with the fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule.
The method of any one of the preceding claims, wherein the FGF2 level is FGF2 mRNA level.
The method of any one of the preceding claims, wherein the VEGF level is VEGF mRNA level.
The method of any one of the preceding claims, wherein the ratio of FGF2 level to VEGF level is greater than 1.
The method of any one of the preceding claims, wherein the cancer is responsive to a FGFR1 ECD or a FGFR1 ECD fusion molecule as a monotherapy.
The method of any one of the preceding claims, wherein the subject is administered a FGFR1 ECD or a FGFR1 ECD fusion molecule as a monotherapy.
The method of any one of the preceding claims, wherein the cancer is selected from kidney cancer (such as renal cell carcinoma), liver cancer (such as hepatocellular carcinoma), lung cancer, colon cancer, liver cancer, breast cancer, stomach cancer, ovarian cancer, endometrial cancer, esophageal cancer, head and neck cancer, glioblastoma, mesothelioma, and prostate cancer.
A method of treating cancer having a lower level of FGF2 compared to the level of VEGF in a subject, comprising administering a therapeutically effective amount of an FGFR1 ECD or an FGFR1 ECD fusion molecule and a therapeutically effective amount of at least one anti-angiogenic agent to the subject.
A method of treating cancer in a subject, comprising:
- administering a therapeutically effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent to the subject,
- wherein, prior to administration of the FGFR1 ECD or FGFR1 ECD fusion molecule and at least one anti-angiogenic agent, at least a portion of the cells of the cancer have been determined to have a lower level of FGF2 compared to the level of VEGF.
A method of identifying a subject who may benefit from treatment with a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent, the method comprising determining the levels of FGF2 and VEGF in a sample obtained from the subject, wherein the lower level of FGF2 compared to the level of VEGF in the sample indicates that the subject may benefit from treatment with the fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent.
A method of reducing blood vessel density in a solid cancer, comprising administering to a subject with the solid cancer an FGFR1 ECD or FGFR1 ECD fusion molecule.
A method of treating mesothelioma comprising administering to a subject with mesothelioma an FGFR1 ECD or FGFR1 ECD fusion molecule and at least one therapeutic agent selected from paclitaxel, carboplatin, docetaxel, pemetrexed, and cisplatin.
The method of any one of the preceding claims, wherein the subject has previously been treated with at least one therapeutic agent selected from pazopanib, bevacizumab, axitinib, aflibercept, sorafenib, and sunitinib.
The method of any one of the preceding claims, wherein the method comprises administering an FGFR1 ECD.
Dependencies are inferred from the claim text.